Theracryf (TCF)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

 0.24p
   
  • Change Today:
      0.000p
  • 52 Week High: 1.22p
  • 52 Week Low: 0.20p
  • Currency: UK Pounds
  • Shares Issued: 2,148.96m
  • Volume: 1,740,479
  • Market Cap: £5.05m
  • Beta: 0.00

Evgen raises £2.3m as Sulforadex trials progress

By Josh White

Date: Monday 11 Dec 2017

LONDON (ShareCast) - (ShareCast News) - Virtual pharmaceutical company Evgen announced on Monday that it was progressing in Phase II clinical trials of SFX-01 for both subarachnoid haemorrhage and ER+ breast cancer, with readouts expected at or around the end of 2018.
The AIM-traded firm also confirmed it had strengthened its balance sheet, with a placing to raise new funds of £2.3m gross.

"Evgen is a virtual pharmaceutical company focused on the development of a synthetic version of a natural product, sulforaphane, which is known to modulate key signalling pathways involved in cellular protection and inflammation," the company's board explained in its short update to the market.

"Evgen's proprietary technology, Sulforadex, creates new and stable variants of sulforaphane, enabling it to be used as a therapeutic for the first time."

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

Theracryf Market Data

Currency UK Pounds
Share Price 0.24p
Change Today 0.000p
% Change 0.00 %
52 Week High 1.22p
52 Week Low 0.20p
Volume 1,740,479
Shares Issued 2,148.96m
Market Cap £5.05m
Beta 0.00

Theracryf Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
44.27% below the market average44.27% below the market average44.27% below the market average44.27% below the market average44.27% below the market average
58.33% above the sector average58.33% above the sector average58.33% above the sector average58.33% above the sector average58.33% above the sector average
Price Trend
95.38% below the market average95.38% below the market average95.38% below the market average95.38% below the market average95.38% below the market average
87.5% below the sector average87.5% below the sector average87.5% below the sector average87.5% below the sector average87.5% below the sector average
Income Not Available
Growth
16.52% below the market average16.52% below the market average16.52% below the market average16.52% below the market average16.52% below the market average
31.25% below the sector average31.25% below the sector average31.25% below the sector average31.25% below the sector average31.25% below the sector average

Theracryf Dividends

No dividends found

Trades for 09-May-2025

Time Volume / Share Price
14:24 5,000 @ 0.23p
13:29 109,301 @ 0.23p
09:30 1,511,364 @ 0.26p
08:35 3,703 @ 0.27p
08:08 111,111 @ 0.26p

Theracryf Key Personnel

CEO Huw Jones
CFO Toni Hänninen

Top of Page